Clonal Dissemination of
            <i>Yersinia enterocolitica</i>
            Strains with Various Susceptibilities to Nalidixic Acid

Sánchez‐Céspedes, Javier; Navia, Margarita M.; Martínez, Rocío; Orden, Beatriz; Millán, Rosario San; Ruiz, Joaquı́m; Vila, Jordi

doi:10.1128/jcm.41.4.1769-1771.2003

Cited by 11 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results agree with those described by Sánchez-Céspedes et al (21). These authors showed the clonal spread of one strain that became resistant to nalidixic acid by acquiring mutations in the gyrA gene.…”

supporting

confidence: 83%

Epidemiological Study of Resistance to Nalidixic Acid and Other Antibiotics in Clinical Yersinia enterocolitica O:3 Isolates

et al. 2003

View full text Add to dashboard Cite

show abstract

supporting

confidence: 83%

Epidemiological Study of Resistance to Nalidixic Acid and Other Antibiotics in Clinical Yersinia enterocolitica O:3 Isolates

et al. 2003

View full text Add to dashboard Cite

show abstract

“…It is interesting, in this respect, that E. faecium isolates that harbored amino acid substitutions in the DNA mismatch repair proteins MutS and MutL belong to CC17 (61), which may suggest that CC17 isolates are more prone to undergo mutations in, e.g., parC or gyrA, conferring high-level resistance to quinolones. Clonal dissemination of quinolone resistance was also reported among methicillin-resistant Staphylococcus aureus, Neisseria gonorrhoeae, Salmonella enterica serotype Typhimurium strain DT 104, Streptococcus pneumoniae, and Yersinia enterocolitica (28,46,48).…”

Section: Discussionmentioning

confidence: 99%

High-Level Ciprofloxacin Resistance from Point Mutations in gyrA and parC Confined to Global Hospital-Adapted Clonal Lineage CC17 of Enterococcus faecium

et al. 2006

View full text Add to dashboard Cite

To substantiate a common genetic background of ciprofloxacin-resistant Enterococcus faecium, 32 ciprofloxacin-resistant (Cip r ) and 31 ciprofloxacin-susceptible (Cip s ) isolates from outbreaks, clinical infections, surveillances, and animals from 10 different countries were genotyped by multilocus sequence typing. Additionally, susceptibilities to ampicillin and vancomycin and the presence of esp were determined and the quinolone resistance-determining regions of parC, gyrA, parB, and gyrE were sequenced. High-level Cip r (MIC > 64 g/ml) due to point mutations in the quinolone resistance-determining region was unique to a distinct hospital-adapted genetic complex in E. faecium, previously designated CC17. Low-level Cip r (MIC ‫؍‬ 4 g/ml) in non-CC17 strains is not attributable to point mutations in any subunit of the topoisomerase genes, and the mechanism of resistance remains unclear. Acquisition of mutations in parC and gyrA, leading to high-level Cip r , is, in addition to ampicillin resistance and the presence of a putative pathogenicity island, another cumulative step in hospital adaptation of CC17.Over the last two decades, enterococci have become increasingly important as nosocomial pathogens (3). These organisms are intrinsically resistant to a large number of antimicrobials and have the ability to easily acquire new resistance traits (40, 50). The emergence of nosocomial infections caused by ampicillin-, high-level aminoglycoside-, and glycopeptide-resistant Enterococcus faecium has caused clinical concern due to intraand interhospital spread and limited therapeutic options (40, 50). Glycopeptide-resistant enterococci (vancomycin-resistant enterococci [VRE]) are nowadays endemic to the United States, with ϳ30% of enterococcal infections caused by VRE (38, 43); in Europe, the epidemiology of VRE is now changing from a near absence of VRE in hospital-acquired infections at the turn of the century to a situation in which nosocomial epidemics and infections are increasingly reported (3, 13, 17). We recently described a hospital-adapted genetic subtype of E. faecium associated with epidemics and clinical infections, which has spread globally (20,32,62,65). This subpopulation belongs to a distinct genetic lineage labeled clonal complex 17 (CC17) (62) and is associated with the presence of the variant esp gene as part of a pathogenicity island (31) and resistance to ampicillin. Recently, resistance to ciprofloxacin appeared to be associated with ampicillin resistance in genotypically related E. faecium isolates from Norway (25,55,56) and Spain (7).To substantiate a common genetic background of quinoloneresistant E. faecium and association with the hospital-adapted CC17, we studied the genetic relatedness of 32 ciprofloxacinresistant and 31 ciprofloxacin-susceptible E. faecium isolates from various human and animal origins by multilocus sequence typing (MLST) and determined susceptibility to vancomycin and ampicillin and the presence of esp. Finally, we sequenced the quinolone resistance-determining regions (...

show abstract

“…Compared to other Enterobacteriaceae, small numbers of Y. enterocolitica resistant to nalidixic acid have been reported to date (Sánchez-Céspedes et al, 2003;Capilla et al, 2004;Fà brega et al, 2010;Sihvonen et al, 2011;Fredriksson-Ahomaa et al, 2012). Although target gene mutations in gyrA are the primary mechanism of resistance to nalidixic acid, efflux pump activity, also contributes to support this phenotype.…”

Section: Resultsmentioning

confidence: 99%

“…Within these loci, the quinoloneresistance-determining region (QRDR) is a mutational hot spot (Fà brega et al, 2010). Several mutations have already been identified in gyrA in Yersinia enterocolitica, the most common of which lead to amino acid substitutions at Ser-83 and Asp-87, conferring resistance to nalidixic acid (Sánchez-Céspedes et al, 2003;Capilla et al, 2004;Sihvonen et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Further Characterization of Three Yersinia enterocolitica Strains with a Nalidixic Acid–Resistant Phenotype Isolated from Humans with Diarrhea

Drummond

Stephan

Haughton

et al. 2013

Foodborne Pathogens and Disease

View full text Add to dashboard Cite

Clonal Dissemination of Yersinia enterocolitica Strains with Various Susceptibilities to Nalidixic Acid

Cited by 11 publications

References 16 publications

Epidemiological Study of Resistance to Nalidixic Acid and Other Antibiotics in Clinical Yersinia enterocolitica O:3 Isolates

Epidemiological Study of Resistance to Nalidixic Acid and Other Antibiotics in Clinical Yersinia enterocolitica O:3 Isolates

High-Level Ciprofloxacin Resistance from Point Mutations in gyrA and parC Confined to Global Hospital-Adapted Clonal Lineage CC17 of Enterococcus faecium

Further Characterization of Three Yersinia enterocolitica Strains with a Nalidixic Acid–Resistant Phenotype Isolated from Humans with Diarrhea

Contact Info

Product

Resources

About